Background & aims Although metabolic risk factors are associated with more severe COVID-
19, there is little evidence on outcomes in patients with non-alcoholic fatty liver disease …

Background Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease
associated with systemic changes in immune response, which might be associated with …

The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with
chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver …

Abstract Background Initial evidence from China suggests that most vulnerable subjects to
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …

Background Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable
population that may be susceptible to more severe COVID-19. Moreover, not only the …

Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in
liver injury. However, few studies investigated liver injury in patients with COVID‐19 with …

A recent study reported that patients with severe COVID-19 were more likely to have non-
alcoholic fatty liver disease (NAFLD) compared with those with non-severe COVID-19 …

Background Evidence for the association between underlying non-alcoholic fatty liver
disease (NAFLD), the risk of testing severe acute respiratory syndrome coronavirus 2 (SARS …

Methods From January 20 through February 17, 2020, consecutive patients admitted to 2
designated COVID-19 Hospitals in China with confirmed COVID-19 and information on …

Background: Covid-19 disease causes significant morbidity and mortality through increase
inflammation and thrombosis. Non-alcoholic fatty liver disease and non-alcoholic …